D Dranka-Bojarowska1, A Lekstan2, M Olakowski2, B Jablonska2, A Lewinski2, P Musialski2, W Sobczyk3, A Kapalka3, P Lampe2. 1. Department of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland. ddranka@poczta.onet.pl. 2. Department of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland. 3. Department of Pharmacology, Medical University of Silesia, Katowice, Poland.
Abstract
UNLABELLED: Pancreatic cancer and chronic pancreatitis are still significant diagnostic and clinical problems. The clinical impact of preoperative serum carbohydrate antygen 19-9 (CA 19-9) levels have been disscussed. The aim of this study was a comparative analysis of the concentrations in serum of adipocytokines: adiponectin and leptin and CA 19-9 in patients with pancreatic cancer (PC), chronic pancreatitis (CP) and control group (CG). The study was performed in a group of 90 patients. Group 1 consisted of 30 patients with PC, group 2 consisted of 30 patients with CP. There was no coincidence of pancreatic cancer in CP group. Group 3 (CG) consisted of 30 persons and were recruited among patients operated for cholelithiasis. The serum samples were taken from patients and the concentration of adiponectin, leptin, CA 19-9 and CEA were evaluated. The revealed concentrations levels of the adiponectin were significantly higher in the PC serum samples compared to the CP and CG. There was no significant correlation between increased adiponectin concentration and body fat mass in the PC group. The concentration of leptin was significantly lower in CP serum samples compared to PC and CG. The concentration of leptin was similar in the PC and CG. The concentration of leptin was mainly dependent on body fat mass and fat distribution. Additionally, measurement of waist circumference and body composition was recorded using bioelectrical impedance analysis. CONCLUSIONS: significantly higher concentration levels of adiponectin in the PC group, independent of body fat mass, may play a potential role as a new tumor marker in PC and might be useful in the differential diagnosis between PC and CP, but this statement needs further investigation. To our knowledge, this was the first study evaluating not only body mass index but also the content and distribution of body fat in patients with PC and CP.
UNLABELLED: Pancreatic cancer and chronic pancreatitis are still significant diagnostic and clinical problems. The clinical impact of preoperative serum carbohydrate antygen 19-9 (CA 19-9) levels have been disscussed. The aim of this study was a comparative analysis of the concentrations in serum of adipocytokines: adiponectin and leptin and CA 19-9 in patients with pancreatic cancer (PC), chronic pancreatitis (CP) and control group (CG). The study was performed in a group of 90 patients. Group 1 consisted of 30 patients with PC, group 2 consisted of 30 patients with CP. There was no coincidence of pancreatic cancer in CP group. Group 3 (CG) consisted of 30 persons and were recruited among patients operated for cholelithiasis. The serum samples were taken from patients and the concentration of adiponectin, leptin, CA 19-9 and CEA were evaluated. The revealed concentrations levels of the adiponectin were significantly higher in the PC serum samples compared to the CP and CG. There was no significant correlation between increased adiponectin concentration and body fat mass in the PC group. The concentration of leptin was significantly lower in CP serum samples compared to PC and CG. The concentration of leptin was similar in the PC and CG. The concentration of leptin was mainly dependent on body fat mass and fat distribution. Additionally, measurement of waist circumference and body composition was recorded using bioelectrical impedance analysis. CONCLUSIONS: significantly higher concentration levels of adiponectin in the PC group, independent of body fat mass, may play a potential role as a new tumor marker in PC and might be useful in the differential diagnosis between PC and CP, but this statement needs further investigation. To our knowledge, this was the first study evaluating not only body mass index but also the content and distribution of body fat in patients with PC and CP.
Authors: Zobeida Cruz-Monserrate; Kristyn Gumpper; Valentina Pita; Phil A Hart; Christopher Forsmark; David C Whitcomb; Dhiraj Yadav; Richard T Waldron; Stephen Pandol; Hanno Steen; Vincent Anani; Natasha Kanwar; Santhi Swaroop Vege; Savi Appana; Liang Li; Jose Serrano; Jo Ann S Rinaudo; Mark Topazian; Darwin L Conwell Journal: Pancreatology Date: 2021-01-22 Impact factor: 3.996
Authors: Alexandra Mikó; Bálint Erőss; Patrícia Sarlós; Péter Hegyi; Katalin Márta; Dániel Pécsi; Áron Vincze; Beáta Bódis; Orsolya Nemes; Nándor Faluhelyi; Orsolya Farkas; Róbert Papp; Dezső Kelemen; Andrea Szentesi; Eszter Hegyi; Mária Papp; László Czakó; Ferenc Izbéki; László Gajdán; János Novák; Miklós Sahin-Tóth; Markus M Lerch; John Neoptolemos; Ole H Petersen; Péter Hegyi Journal: BMJ Open Date: 2019-09-03 Impact factor: 2.692